spacer
home > ebr > autumn 2009 > primum non nocere: first, do no harm
PUBLICATIONS
European Biopharmaceutical Review

Primum non nocere: First, do no harm

 

Ever since the publication of the report, ‘To Err is Human; Building a Safer Health System’, the medical world has begun to open its eyes to the magnitude and impact of errors (1). The report was issued in 1999 by the Institute of Medicine (IOM) of the National Academy of Sciences in the US, and called for a broad effort to improve the situation, which included the reporting of errors and adverse events. With the latter, we mean an injury related to care (diagnosis, treatment, failure, systems and equipment used). The world needed some time to accept that in the Western, more people die due to preventable errors in hospitals than by traffic accidents, or other situations which are generally perceived as being more dangerous.

This report was certainly not the only one published and many followed. In the Netherlands, for example, the President Director of Shell Netherlands, Mr Rein Willems, published a report in 2004 which included four ways to reduce errors by no less than 75 per cent within a period of 15 years. Willems claimed the necessity of the introduction of a certified clinical risk management system and strong governmental supervision.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gian Schiava is Marketing Manager at The Patient Safety Company, where he works on the international expansion of this Dutch company. He has more than 20 years of marketing and sales experience in various industries, varying from office furniture to heavy-duty forklifts. As a member of the Management Team, he is interested in the current challenge to market products that lead to a reduction of incidents and improved patient safety levels, both in large medical hospitals and smaller, specialised healthcare organisations. Gian holds a Bachelor in Economics and undertook post-doctoral studies.
spacer
Gian Schiava
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator, with the UK and France close behind

Paris, 19th August 2019: As predicted by the ‘European drug delivery and packaging’ report earlier this year, new data shows innovation in drug delivery is accelerating across Europe – with provisional findings from the Pharmapack Innovation Index (2020) showing that Switzerland has over taken Germany as Europe’s most innovative drug delivery market.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement